Zevra Therapeutics
ZVRA· Manufacturing· Fiscal year ends in December
CEO pay in FY2024Stock +27.3% in FY2024
Neil F. McFarlane is the CEO of Zevra Therapeutics and was paid $5.4M in FY2024 (Dec), up 55%.
Pay$100 in the stock at the end of FY22 → $182
Executives3
See all- 1Neil F. McFarlanePresident, Chief Executive Officer and DirectorFY2024
- 2R. LaDuane Clifton, MBA, CPAFormer Chief Financial Officer and TreasurerFY2025
- 3Rahsaan W. ThompsonChief Legal Officer, Secretary and Compliance OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allZevra Therapeutics paid its 2 named executives $5.4M in total in FY2025 (Dec).
| Name | |||
|---|---|---|---|
| R. LaDuane Clifton, MBA, CPAFormer Chief Financial Officer and Treasurer | |||
| Rahsaan W. ThompsonChief Legal Officer, Secretary and Compliance Officer | Not disclosed | Not disclosed | |
| Neil F. McFarlanePresident, Chief Executive Officer and Director | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Zevra Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Corey WattonDirector · 2 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Douglas W. CalderDirector · 2 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
- Alvin ShihDirector · 1 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 20, 2026 | FY2025 |
| Annual report | 10-K | Mar 9, 2026 | FY2025 |
| Annual report | 10-K | Mar 12, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 3, 2024 | FY2023 |
| Annual report | 10-K | Apr 1, 2024 | FY2023 |
